Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis

Keyphrases

• Individual Patient Data Meta-analysis 100%
• Falciparum Malaria 100%
• Primaquine 100%
• Glucose-6-phosphate Dehydrogenase Activity 45%
• Daily Dose 36%
• Radical Cure 27%
• Between-day 18%
• Plasmodium Vivax 18%
• Hemoglobin Concentration 18%
• Adjusted Means 18%
• Hemoglobin Reduction 18%
• Health Research 9%
• Treatment Group 9%
• Hemoglobin 9%
• Medical Records 9%
• Meta-analysis 9%
• Artemisinin-based Combination Therapy 9%
• Chloroquine 9%
• Endemic Countries 9%
• Cochrane 9%
• Prospero 9%
• Embase 9%
• Medical Research Council 9%
• National Health 9%
• Hematocrit 9%
• MEDLINE 9%
• Risk of Bias 9%
• Artemether-lumefantrine 9%
• Bill & Melinda Gates Foundation 9%
• Individual Patient Data 9%
• Web of Science 9%
• Day 14 9%
• Concentration Change 9%
• Active Follow-up 9%
• Hemoglobin Change 9%
• Safe Use 9%
• Liver Stage 9%
• Dormant 9%
• Medicines for Malaria Venture 9%
• Severe Malaria 9%
• Patient-level Data 9%
• Mixed Effects Linear Regression 9%
• Prospective Clinical Study 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Plasmodium Vivax Malaria 100%
• Primaquine 100%
• Glucose 6 Phosphate Dehydrogenase 45%
• Combination Therapy 9%
• Clinical Study 9%
• Chloroquine 9%
• Artemisinin 9%